![Henrik Elofsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henrik Elofsson
No más puestos en curso
Historial de carrera de Henrik Elofsson
Antiguos cargos conocidos de Henrik Elofsson.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MENDUS AB | Director de Operaciones | 01/07/2013 | - |
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Director/Miembro de la Junta | 03/09/2010 | - |
Fundador | 01/01/2007 | - | |
Corporate Officer/Principal | 03/09/2010 | 11/06/2013 |
Formación de Henrik Elofsson.
University of Linköping | Undergraduate Degree |
Chalmers School of Entrepreneurship | Graduate Degree |
Estadísticas
Internacional
Suecia | 5 |
Operativa
Director/Board Member | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MENDUS AB | Health Technology |
Empresas privadas | 1 |
---|---|
Arterion AB
![]() Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Henrik Elofsson
- Experiencia